-
Abstract: Dahuang Zhechong pill, as a classical ancient prescription, has the functions of promoting blood circulation, breaking blood stasis, relieving middle and tonifying deficiency, and is widely used in clinic. This paper reviews the research progress of Dahuang Zhechong pill in liver diseases in recent five years from two aspects of clinical diseases and molecular pathological mechanism, in order to provide reference for its better application in clinical practice.
-
Key words:
- Dahuang Zhechong pill /
- liver disease /
- experimental research /
- clinical application /
- research progress
-
[1] 李德辉,郭娜,范焕芳,等.大黄蛰虫丸抗肿瘤作用研究进展[J].中国老年学杂志,2018,38(6):1524-1526.
[2] 洪钰蕾,黄利坚.金匮大黄蛰虫丸的现代临床应用及医案例举[J].按摩与康复医学,2021,12(4):87-90.
[3] 朱淑琴,苏日嘎.大黄蛰虫丸联合恩替卡韦治疗慢性乙型肝炎肝硬化的临床研究[J].临床医药文献电子杂志,2017,4(15):2914-2916.
[4] 闻海军.加味大黄蛰虫丸联合IFN-α对慢性病毒性乙型肝炎的疗效[J].检验医学与临床,2017,14(22):3420-3422.
[5] 郭晶晶,田芝奥,李亚南.大黄蛰虫丸联合替诺福韦酯治疗慢性乙型肝炎肝纤维化的临床效果观察[J].中国医师进修杂志,2020,43(12):1109-1114.
[6] 陈先翰,唐嘉华,唐梅文,等.大黄蛰虫丸联合恩替卡韦片治疗慢性乙肝瘀血阻络证患者临床观察[J].现代医学与健康研究电子杂志,2019,3(22):9-11.
[7] 陈宏斌.恩替卡韦联合大黄蛰虫丸治疗乙型肝炎肝纤维化的临床效果[J].临床医学研究与实践,2018,3(5):133-134.
[8] 刘宁,何肖洁,张玉花,等.大黄蛰虫丸联合恩替卡韦治疗青年乙肝肝纤维化患者的疗效观察[J].世界最新医学信息文摘,2019,19(21):16-17.
[9] 牛祎明.疏肝解毒汤方与大黄蛰虫丸辅助恩替卡韦对慢性乙型肝炎患者的疗效及其对肝功能的改善与生活质量的影响[J].抗感染药学,2018,15(5):891-893.
[10] Khatun MS,Biswas MHA.Optimal Control Strategies for Preventing Hepatitis B Infection and Reducing Chronic Liver Cirrhosis Incidence[J].Infect Dis Model,2020,5(1):91-110.
[11] 张红星,刘旭东,王朝阳.大黄蛰虫丸联合恩替卡韦治疗慢性乙型肝炎肝硬化疗效观察[J].中国中西医结合消化杂志,2016,24(8):575-577.
[12] 杨波.恩替卡韦联合大黄蟅虫丸治疗慢性乙型肝炎早期肝硬化26例[J].中国中西医结合消化杂志,2016,24(6):479-480.
[13] 黄红刚.大黄蟅虫丸联合抗病毒治疗对慢性乙肝肝硬化患者血清病毒复制指标及免疫、炎症指标的影响[J].海南医学院学报,2017,23(8):1048-1051.
[14] 洪海龙.恩替卡韦联合大黄蛰虫丸治疗乙肝肝硬化的临床观察[J].医学理论与实践,2019,32(7):1003-1005.
[15] 刘旭东,赵壮志,吕萍,等.大黄蛰虫丸联合抗病毒药物治疗乙肝肝硬化疗效的Meta分析[J].时珍国医国药,2018,29(7):1594-1597.
[16] 梅昭荷,聂红明,汪蓉,等.大黄蛰虫胶囊治疗代偿期乙型肝炎肝硬化瘀血阻络证伴脾大的真实世界回顾性队列研究[J].中医杂志,2020,61(21):1894-1899.
[17] 张金付.疏肝健脾解毒化湿方合大黄蟅虫丸治疗乙肝代偿期肝硬化临床观察[J].实用中医内科杂志,2021,35(2):129-131.
[18] Bray F,Ferlay J,Soerjomataram I,et al.Global Cancer Statistics 2018:Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].Cancer J Clin,2018,68(6):394-424.
[19] 张希琼.大黄蛰虫丸抗肝癌活性成分筛选及其药动学研究[D].南京:南京中医药大学,2019.
[20] 杨勤龙.大黄蛰虫丸为主治疗晚期恶性肿瘤[J].中医临床研究,2013,5(19):16-17.
[21] 谢美清,赵晓芳,刘旭东.大黄蛰虫丸对肝癌介入治疗致肝纤维化相关指标的影响[J].广西中医药,2014,37(2):46-47.
[22] 侯宝松,刘霞,王海峰,等.逍遥方合大黄蛰虫方加减联合肝动脉化疗栓塞术对原发性肝癌肝郁脾虚证患者免疫功能和生活质量的影响[J].河北中医,2020,42(9):1346-1350,1368-1368.
[23] 杨军民,何耀辉,马宝梅.大黄蛰虫丸联合化疗治疗原发性肝癌35例[J].西部中医药,2018,31(10):83-85.
[24] 戴朝明,靳松,张济周.大黄蛰虫丸联合TACE术对原发性肝癌患者(瘀血阻络型)VEGF,MMP-2,TGF-β1及免疫功能的影响[J].中国中药杂志,2021,46(3):722-729.
[25] 杨昭,张岚.大黄蛰虫丸合消瘿汤对老年晚期原发性肝癌患者生存率的影响[J].辽宁中医杂志,2019,46(10):2098-2101,.
[26] 徐艳丽,王旭,王柯尹,等.大黄蟅虫丸联合门冬氨酸鸟氨酸针治疗肝性脑病的疗效观察[J].浙江实用医学,2017,22(5):334-336.
[27] 骆洁恒,邓锦伟,陈小梅.大黄蛰虫丸联合贞芪扶正颗粒治疗乙型肝炎后肝硬化腹水疗效观察[J].新中医,2016,48(3):52-54.
[28] 李琤,李广明,高鹏.健脾化臌汤联合大黄蛰虫丸对乙型肝炎后肝硬变腹水患者T细胞亚群及血清HA、Alb水平变化的影响[J].河南中医,2020,40(2):262-266.
[29] 高玉杰.自拟疏肝健脾化瘀汤联合大黄虫蛰丸治疗乙型肝炎后肝硬化腹水临床观察[J].光明中医,2019,34(13):2002-2004.
[30] 魏莹,徐守竹,刘俊田.大黄蟅虫丸对大鼠慢性脂肪肝的治疗作用[J].西北药学杂志,2015,30(4):382-386.
[31] 靳华.疏肝消脂汤联合大黄蛰虫丸治疗脂肪肝的临床疗效分析[J].中医临床研究,2015,7(11):74-75.
[32] 吴慧心.疏肝消脂汤联合大黄蛰虫丸治疗脂肪肝30例[J].中国中医药现代远程教育,2015,13(10):47-48.
[33] 刘俊伟,苏镜波.大黄蟅虫胶囊联合卵磷脂治疗肝功异常的非酒精性脂肪肝高脂血症的疗效观察[J].右江医学,2014,42(3):327-329.
[34] 钟伟超,周楚莹,高磊,等.大黄蛰虫丸对小鼠酒精性肝纤维化损伤的保护作用[J].中成药,2017,39(12):2475-2480.
[35] 刘文,程瑞.大黄蛰虫丸佐治酒精性肝纤维化临床疗效观察[J].国医论坛,2018,33(3):6-8.
[36] 刘旭东,赵壮志,吕萍,等.大黄蛰虫丸对大鼠肝组织BAMBI表达的影响[J].时珍国医国药,2018,29(12):2858-2861.
[37] 徐新杰,刘旭东,赵壮志,等.大黄蛰虫丸对大鼠原代肝星状细胞BAMBI表达的影响[J].北京中医药大学学报,2018,41(7):572-578.
[38] 吕萍,刘旭东,徐新杰,等.大黄蛰虫丸含药血清调控大鼠原代肝星状细胞BAMBI表达的研究[J].中华中医药学刊,2019,37(5):1088-1091.
[39] 刘旭东,徐新杰,赵壮志,等.大黄蛰虫丸对脂多糖与肝星状细胞TLR4交联的影响[J].广东医学,2019,40(2):176-179.
[40] Ralitsa P,Joyner AL.Roles for Hedgehog Signaling in Adult Organ Homeostasis and Repair.[J].Development(cambridge,England),2014,114(18):3445-3457.
[41] Huang Y,Tiao M,Huang L,et al.Activation of Mir-29a in Activated Hepatic Stellate Cells Modulates Its Profibrogenic Phenotype Through Inhibition of Histone Deacetylases 4[J].Plos One,2017,10(8):136453.
[42] Cardenas CLL,Henaoui IS,Courcot E,et al.Mir-199a-5p Is Upregulated During Fibrogenic Response to Tissue Injury and Mediates Tgfbeta-induced Lung Fibroblast Activation By Targeting Caveolin-1[J].Plos Gene,2017,9(2):1003291.
[43] 卜文超,钟俊,刘晓雨,等.Hh信号通路因子Shh、Ptch1和Gli1在大黄蛰虫丸抗大鼠肝纤维化中的表达及调节作用[J].解剖学研究,2019,41(1):63-67.
[44] Yoshikuni N,Hikaru U,Michio I,et al.Inhibition of Transforming Growth Factor Beta Decreases Pancreatic Fibrosis and Protects the Pancreas Against Chronic Injury in Mice[J].Lab Invest,2004,84(12):1610-1618.
[45] Roskoski R.The Role of Small Molecule Platelet-derived Growth Factor Receptor(pdgfr)Inhibitors in the Treatment of Neoplastic Disorders[J].Pharmacol Res,2018,129(1):65-83.
[46] 王金光,车念聪,李文新,等.大黄蛰虫丸加味对免疫性肝纤维化大鼠肝组织PDGF及PDGFR的影响[J].环球中医药,2016,9(10):1190-1193.
[47] 王乐,丁腾,龚伟玲,等.调控TGF-β1/Smads信号通路抗肝纤维化的中药有效成分研究进展[J].中国中药杂志,2019,44(4):666-674.
[48] 曾震军,李墨航,王新亭.血清中TGF-β1、MMP-1表达水平联合FibroScan对乙肝肝纤维化诊断价值[J].热带医学杂志,2020,20(3):376-379.
[49] 曹涛,朱海宏.基于下调TGF-β1/Smad通路抗肝纤维化研究进展[J].中西医结合心血管病电子杂志,2020,8(30):93-95.
[50] 陈纯辉.大黄(庶虫)虫丸改善外泌体CCL2启动介导的转移前微环境抑制结直肠癌肝转移[D].广州:南方医科大学,2019.
[51] Corre I,Paris F,Jacques H.The P38 Pathway,a Major Pleiotropic Cascade That Transduces Stress and Metastatic Signals in Endothelial Cells[J].Oncotarget,2017,8(33):55684-55714.
计量
- 文章访问数: 409
- PDF下载数: 120
- 施引文献: 0